We're unable to sign you in at this time. Please try again in a few minutes.
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Article |

Hepatotoxicity After Methoxyflurane Administration

Neil C. Klein, MD; Graham H. Jeffries, MRCP
JAMA. 1966;197(12):1037-1039. doi:10.1001/jama.1966.03110120143040.
Text Size: A A A
Published online


METHOXYFLURANE (Penthrane) is a shortchain halogenated ether which was developed as a general anesthetic by Van Poznak and Artusio1 and has been in clinical use since 1959. Although chemically an ether, this compound has organic chloride and fluoride substituents similar to that of halothane.

In view of this structural similarity it might be expected that increasing use of methoxyflurane will be associated with rare reports of drug-induced hepatic injury. To our knowledge, this is the first nonfatal case of suspected methoxyflurane hepatotoxicity with documented hepatocellular necrosis.

Report of a Case  In June 1965, a 58-year-old Negro woman (NYH 159-803) was seen in the outpatient department complaining of a persistent vaginal discharge. A friable lesion, which on biopsy proved to be a squamous-cell carcinoma was noted in the vaginal vault. She was admitted for treatment in July 1965. She had suffered from attacks of acute pelvic inflammatory disease in 1939 and 1946 with episodic, recurrent lower abdominal pain. A hysterectomy and bilateral salpingo-oophorectomy was performed in 1953.


Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?




Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Please click the checkbox indicating that you have read the full article in order to submit your answers.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.


Some tools below are only available to our subscribers or users with an online account.

0 Citations

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

Related Content

Customize your page view by dragging & repositioning the boxes below.